Tag: clinical study
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
Viaskin Peanut Completes Phase III Part A Study of Toddlers With...
Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
Enrollment Complete for Phase 2b Probiotic Oral Immunotherapy Treatment Candidate
Study to provide evidence of longer lasting tolerance to peanut in a larger number of patients.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Study: IgG Antibodies Activate Blood Platelets and Contribute to the Severity...
"This work demonstrates the potential of exploring therapeutic interventions that target platelets as means of limiting the severity of anaphylactic shock."
Study: Pediatric Admissions Slashed With Simple Changes to Hospital Anaphylaxis Procedures
Researchers were able to streamline the care of patients with anaphylaxis without any compromise in safety.
Study: Immunotherapy Trials for Food Allergy Hold Strong Appeal for Parents
Child’s food allergies have major impact on parents’ lives; majority of parents are willing to enroll their child in an immunotherapy clinical trial
Aimmune to Submit FDA Application for Peanut OIT Candidate by End...
If approved, AR101 could be offered as the first FDA approved OIT therapy for peanut allergy.
Milk and Peanut Clinical Trial Advances
Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.
